. . . " "@en . "6 to 8 hours"@en . "Sulpirida"@en . "Sulpiride"@en . . . "A dopamine D2-receptor antagonist. It has been used therapeutically as an antidepressant, antipsychotic, and as a digestive aid. (From Merck Index, 11th ed)"@en . . "Levosulpiride"@en . . "Humans and other mammals"@en . . "Sulpirid"@en . "5-(Aminosulfonyl)-N-((1-ethyl-2-pyrrolidinyl)methyl)-2-methoxybenzamide"@en . . . . . . . . . . . . "Sulpiride is absorbed slowly from the gastrointestinal tract. Its oral bioavailability is only 25 to 35% with marked interindividual differences. "@en . . . . . "Levosulpiridum"@en . "In contrast to most other neuroleptics which block both dopamine D1 and D2 receptors, Sulpiride is more selective and acts primarily as a dopamine D2 antagonist. Sulpiride appears to lack effects on norepinephrine, acetylcholine, serotonin, histamine, or gamma-aminobutyric acid (GABA) receptors."@en . . . "Sulpiridum"@en . . "15676-16-1"@en . . "N-((1-Ethyl-2-pyrrolidinyl)methyl)-2-methoxy-5-sulfamoylbenzamide"@en . . . . . "Sulpiride is indicated for the treatment of schizophrenia."@en . "N-((1-Ethyl-2-pyrrolidinyl)methyl)-5-sulfamoyl-O-anisamide"@en . . . . . . . . . . "Sulpyrid"@en . "(+-)-Sulpiride"@en . . . "Levosulpirida"@en . "approved"@en . . "Sulpiride has a relatively low order of acute toxicity. Substantial amounts may cause severe but reversible dystonic crises with torticollis, protrusion of the tongue, and/or trism. In some cases all the classical symptoms typical of severe Parkinson's Disease may be noted; in others, over-sedation/coma may occur."@en . . . .